Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Aromatase Inhibitors or Tamoxifen

被引：0
作者：
Lintermans, A.
Dieudonne, A. S.
Vanderhaegen, J. [1 ]
Henry, N. L. [2 ]
Wildiers, H. [3 ]
Paridaens, R. [3 ]
Christiaens, M. R. [3 ]
Smeets, A. [3 ]
Leunen, K. [3 ]
Neven, P. [3 ]
机构：
[1] Katholieke Univ Leuven Hosp, Gynecol Multidisciplinary Breast Ctr, Louvain, Belgium
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Katholieke Univ Leuven Hosp, Multidisciplinary Breast Ctr, Louvain, Belgium
来源：
EUROPEAN JOURNAL OF CANCER | 2012年 / 48卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S159 / S160
页数：2
相关论文
共 50 条
  • [31] Menopausal symptoms and uterine changes in postmenopausal breast cancer patients receiving tamoxifen or third generation aromatase inhibitors
    不详
    EJC SUPPLEMENTS, 2004, 2 (09): : 19 - 21
  • [32] Prospective endometrial assessment of breast cancer patients treated with third generation aromatase inhibitors
    Garuti, Giancarlo
    Cellani, Fulvia
    Centinaio, Giovanna
    Montanari, Giuseppe
    Nalli, Giulio
    Luerti, Massimo
    GYNECOLOGIC ONCOLOGY, 2006, 103 (02) : 599 - 603
  • [33] Meta-Analysis of Breast Cancer Outcomes in Adjuvant Trials of Aromatase Inhibitors Versus Tamoxifen
    Dowsett, Mitch
    Cuzick, Jack
    Ingle, Jim
    Coates, Alan
    Forbes, John
    Bliss, Judith
    Buyse, Marc
    Baum, Michael
    Buzdar, Aman
    Colleoni, Marco
    Coombes, Charles
    Snowdon, Claire
    Gnant, Michael
    Jakesz, Raimund
    Kaufmann, Manfred
    Boccardo, Francesco
    Godwin, Jon
    Davies, Christina
    Peto, Richard
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (03) : 509 - 518
  • [34] Clinical characteristics of bone fractures in breast cancer women receiving adjuvant aromatase inhibitors
    Wojtacki, J.
    Wiraszka, R.
    Markowicz, A.
    Piotrowska, M.
    EJC SUPPLEMENTS, 2008, 6 (07): : 200 - 201
  • [35] AUDIT OF BREAST CANCER PATIENTS ON AROMATASE INHIBITORS WITH BASELINE DEXA SCANS
    Tanna, N.
    Batten, C.
    Pitkin, J.
    OSTEOPOROSIS INTERNATIONAL, 2010, 21 : S481 - S482
  • [36] Breast cancer patients receiving denosumab during adjuvant aromatase inhibitors treatment: who are the "inadequate responders" patients to denosumab?
    Irelli, Azzurra
    Sirufo, Maria Maddalena
    Scipioni, Teresa
    De Pietro, Francesca
    Pancotti, Amedeo
    Ginaldi, Lia
    De Martinis, Massimo
    JOURNAL OF BUON, 2020, 25 (02): : 648 - 654
  • [37] Fracture threshold in breast cancer patients treated with adjuvant aromatase inhibitors
    Bertoldo, F.
    Dalle Carbonare, L.
    Zenari, S.
    Pancheri, S.
    Zanatta, M.
    Giovanazzi, B.
    Valenti, M. T.
    Lo Cascio, V.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2007, 22 : S161 - S161
  • [38] Endometrial cancer risk in postmenopausal breast cancer patients treated with tamoxifen or aromatase inhibitors
    Sestak, Ivana
    Cuzick, Jack
    EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2016, 11 (05) : 425 - 432
  • [39] Cognitive impairment among breast cancer patients receiving endocrine treatment: A comparative study between aromatase inhibitors and tamoxifen
    Ben Abdallah, I.
    Rachdi, H.
    Mejri, N.
    Berrazega, Y.
    El Benna, H.
    Daoud, N.
    Laabidi, S.
    Boussen, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S82 - S82
  • [40] Hemorrhage Risk Among Patients With Breast Cancer Receiving Concurrent Direct Oral Anticoagulants With Tamoxifen vs Aromatase Inhibitors
    Wang, Tzu-Fei
    Clarke, Anna E.
    Awan, Arif A.
    Tanuseputro, Peter
    Carrier, Marc
    Sood, Manish M.
    JAMA NETWORK OPEN, 2022, 5 (06)
12345